{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:21:31Z","timestamp":1792419691167,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1038\/ajg.2012.334","type":"journal-article","created":{"date-parts":[[2012,10,2]],"date-time":"2012-10-02T13:31:27Z","timestamp":1349184687000},"page":"99-105","source":"Crossref","is-referenced-by-count":188,"title":["T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-\u03b1) Inhibitors: Results of the REFURBISH Study"],"prefix":"10.14309","volume":"108","author":[{"given":"Parakkal","family":"Deepak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto","family":"Sifuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Sherid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Stobaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yama","family":"Sadozai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli Daniel","family":"Ehrenpreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20210210","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/gut.2004.051771","article-title":"Risk of haematopoietic cancer in patients with inflammatory bowel disease.","volume":"54","author":"Askling","year":"2005","journal-title":"Gut"},{"key":"R2-20-20210210","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R3-20-20210210","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R4-20-20210210","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"R5-20-20210210","first-page":"A116","article-title":"Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel diseases (IBD): interim results of the CESAME cohort.","volume":"1","author":"Beaugerie","year":"2008","journal-title":"Gastroenterology"},{"key":"R6-20-20210210","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"R7-20-20210210","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohns disease: a meta-analysis.","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R8-20-20210210","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/ajg.2011.283","article-title":"Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.","volume":"106","author":"Herrinton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R9-20-20210210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R10-20-20210210","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/MEG.0b013e32834bb90a","article-title":"Hepatosplenic T-cell lymphoma in patients receiving TNF- inhibitor therapy: expanding the groups at risk.","volume":"23","author":"Parakkal","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R13-20-20210210","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"R14-20-20210210","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jaad.2004.03.047","article-title":"Aggressive cutaneous T-cell lymphomas after TNF-alpha blockade.","volume":"51","author":"Adams","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R15-20-20210210","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1245\/s10434-009-0470-0","article-title":"Importance of early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia.","volume":"16","author":"Gumbs","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"R16-20-20210210","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2133.2005.06686.x","article-title":"Mycosis fungoides-associated follicular mucinosis under adalimumab.","volume":"153","author":"Dalle","year":"2005","journal-title":"Br J Dermatol"},{"key":"R17-20-20210210","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-2133.2009.09044.x","article-title":"Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis.","volume":"160","author":"Michot","year":"2009","journal-title":"Br J Dermatol"},{"key":"R18-20-20210210","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2133.2006.07713.x","article-title":"Sezary syndrome in a patient receiving infliximab for ankylosing spondylitis.","volume":"156","author":"Dauendorffer","year":"2007","journal-title":"Br J Dermatol"},{"key":"R19-20-20210210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3816\/CLM.2006.n.008","article-title":"Atypical CD8 cutaneous T-cell lymphoma after immunomodulatory therapy.","volume":"6","author":"Berthelot","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"R20-20-20210210","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1468-3083.2008.03074.x","article-title":"Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.","volume":"23","author":"Lourari","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R21-20-20210210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12308-009-0029-9","article-title":"T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary.","volume":"2","author":"Schmidt","year":"2009","journal-title":"J Hematop"},{"key":"R22-20-20210210","first-page":"A311","article-title":"Hepatosplenic T cell lymphoma, immunosuppressive agents and biologicals: What are the risks?","volume":"24","author":"Grimpen","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"R23-20-20210210","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: A population based study.","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"R24-20-20210210","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/gast.2001.28703","article-title":"Inflammatory bowel disease is not associated with an increased risk of lymphoma.","volume":"121","author":"Lewis","year":"2001","journal-title":"Gastroenterology"},{"key":"R25-20-20210210","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/oxfordjournals.epirev.a017980","article-title":"Epidemiology of the Revised European-American Lymphoma Classification subtypes.","volume":"20","author":"Herrinton","year":"1998","journal-title":"Epidemiol Rev"},{"key":"R26-20-20210210","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.","volume":"44","author":"Mackey","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R27-20-20210210","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00125-009-1491-8","article-title":"Collateral damage: the conundrum of drug safety.","volume":"52","author":"Gale","year":"2009","journal-title":"Diabetologia"},{"key":"R28-20-20210210","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1345\/aph.1L315","article-title":"Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms.","volume":"42","author":"Chen","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R29-20-20210210","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohns disease.","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2012334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2012334","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2012334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201301000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:43:59Z","timestamp":1786542239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201301000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2012.334","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}